Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 36.80
TARO's Cash to Debt is ranked higher than
86% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. TARO: 36.80 )
TARO' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 36.8

Equity to Asset 0.80
TARO's Equity to Asset is ranked higher than
87% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. TARO: 0.80 )
TARO' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.81
Current: 0.8

0.23
0.81
Interest Coverage 283.81
TARO's Interest Coverage is ranked higher than
71% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. TARO: 283.81 )
TARO' s 10-Year Interest Coverage Range
Min: 1.47   Max: 508.04
Current: 283.81

1.47
508.04
F-Score: 6
Z-Score: 16.43
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 55.84
TARO's Operating margin (%) is ranked higher than
99% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. TARO: 55.84 )
TARO' s 10-Year Operating margin (%) Range
Min: -27.89   Max: 56.67
Current: 55.84

-27.89
56.67
Net-margin (%) 47.22
TARO's Net-margin (%) is ranked higher than
99% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. TARO: 47.22 )
TARO' s 10-Year Net-margin (%) Range
Min: -32.77   Max: 47.46
Current: 47.22

-32.77
47.46
ROE (%) 34.70
TARO's ROE (%) is ranked higher than
98% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. TARO: 34.70 )
TARO' s 10-Year ROE (%) Range
Min: -92.98   Max: 49.88
Current: 34.7

-92.98
49.88
ROA (%) 27.60
TARO's ROA (%) is ranked higher than
99% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. TARO: 27.60 )
TARO' s 10-Year ROA (%) Range
Min: -17   Max: 30.15
Current: 27.6

-17
30.15
ROC (Joel Greenblatt) (%) 125.57
TARO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. TARO: 125.57 )
TARO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -30.11   Max: 132.39
Current: 125.57

-30.11
132.39
Revenue Growth (%) 22.30
TARO's Revenue Growth (%) is ranked higher than
87% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TARO: 22.30 )
TARO' s 10-Year Revenue Growth (%) Range
Min: -6.8   Max: 34.7
Current: 22.3

-6.8
34.7
EBITDA Growth (%) 63.60
TARO's EBITDA Growth (%) is ranked higher than
97% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. TARO: 63.60 )
TARO' s 10-Year EBITDA Growth (%) Range
Min: -24.3   Max: 63.6
Current: 63.6

-24.3
63.6
EPS Growth (%) 74.30
TARO's EPS Growth (%) is ranked higher than
97% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. TARO: 74.30 )
TARO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 102.1
Current: 74.3

0
102.1
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TARO Guru Trades in Q3 2013

HOTCHKIS & WILEY 438,675 sh (New)
Steven Cohen 5,644 sh (New)
Jim Simons 213,100 sh (+30.58%)
» More
Q4 2013

TARO Guru Trades in Q4 2013

HOTCHKIS & WILEY 529,936 sh (+20.8%)
Jim Simons 235,473 sh (+10.5%)
Steven Cohen 4,701 sh (-16.71%)
» More
Q1 2014

TARO Guru Trades in Q1 2014

Jim Simons 268,400 sh (+13.98%)
Steven Cohen Sold Out
HOTCHKIS & WILEY 455,252 sh (-14.09%)
» More
Q2 2014

TARO Guru Trades in Q2 2014

Jim Simons 371,200 sh (+38.3%)
HOTCHKIS & WILEY 510,952 sh (+12.23%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2013-12-31 Add 20.8%0.04%$75.22 - $99.05 $ 145.9768%529936
HOTCHKIS & WILEY 2013-09-30 New Buy0.15%$56.9 - $73.8 $ 145.97125%438675
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.40
TARO's P/E(ttm) is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. TARO: 18.40 )
TARO' s 10-Year P/E(ttm) Range
Min: 3.14   Max: 477.06
Current: 18.4

3.14
477.06
P/B 5.79
TARO's P/B is ranked higher than
59% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. TARO: 5.79 )
TARO' s 10-Year P/B Range
Min: 1.07   Max: 6.4
Current: 5.79

1.07
6.4
P/S 8.70
TARO's P/S is ranked higher than
60% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. TARO: 8.70 )
TARO' s 10-Year P/S Range
Min: 0.61   Max: 9.63
Current: 8.7

0.61
9.63
PFCF 21.37
TARO's PFCF is ranked higher than
93% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 21.37 )
TARO' s 10-Year PFCF Range
Min: 4.51   Max: 27.78
Current: 21.37

4.51
27.78
EV-to-EBIT 13.66
TARO's EV-to-EBIT is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. TARO: 13.66 )
TARO' s 10-Year EV-to-EBIT Range
Min: 4.6   Max: 59.6
Current: 13.66

4.6
59.6
PEG 0.33
TARO's PEG is ranked higher than
99% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 0.33 )
TARO' s 10-Year PEG Range
Min: 0.43   Max: 36.64
Current: 0.33

0.43
36.64
Shiller P/E 33.69
TARO's Shiller P/E is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.53 vs. TARO: 33.69 )
TARO' s 10-Year Shiller P/E Range
Min: 6.08   Max: 75.08
Current: 33.69

6.08
75.08
Current Ratio 4.37
TARO's Current Ratio is ranked higher than
86% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. TARO: 4.37 )
TARO' s 10-Year Current Ratio Range
Min: 0.79   Max: 7.27
Current: 4.37

0.79
7.27
Quick Ratio 3.86
TARO's Quick Ratio is ranked higher than
86% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. TARO: 3.86 )
TARO' s 10-Year Quick Ratio Range
Min: 0.55   Max: 6.3
Current: 3.86

0.55
6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.99
TARO's Price/Net Cash is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 15.99 )
TARO' s 10-Year Price/Net Cash Range
Min: 6.83   Max: 92.19
Current: 15.99

6.83
92.19
Price/Net Current Asset Value 11.74
TARO's Price/Net Current Asset Value is ranked higher than
88% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TARO: 11.74 )
TARO' s 10-Year Price/Net Current Asset Value Range
Min: 4.91   Max: 82.69
Current: 11.74

4.91
82.69
Price/Tangible Book 5.79
TARO's Price/Tangible Book is ranked higher than
67% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. TARO: 5.79 )
TARO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 15.98
Current: 5.79

0.89
15.98
Price/DCF (Projected) 2.01
TARO's Price/DCF (Projected) is ranked higher than
87% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.71 vs. TARO: 2.01 )
TARO' s 10-Year Price/DCF (Projected) Range
Min: 1.44   Max: 201.56
Current: 2.01

1.44
201.56
Price/Median PS Value 4.23
TARO's Price/Median PS Value is ranked higher than
53% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. TARO: 4.23 )
TARO' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 4.32
Current: 4.23

0.18
4.32
Price/Graham Number 2.15
TARO's Price/Graham Number is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.69 vs. TARO: 2.15 )
TARO' s 10-Year Price/Graham Number Range
Min: 0.4   Max: 10.12
Current: 2.15

0.4
10.12
Earnings Yield (Greenblatt) 7.30
TARO's Earnings Yield (Greenblatt) is ranked higher than
87% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TARO: 7.30 )
TARO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 21.8
Current: 7.3

1.7
21.8
Forward Rate of Return (Yacktman) 1.48
TARO's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. TARO: 1.48 )
TARO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.7   Max: 51.7
Current: 1.48

-31.7
51.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:TAL.Germany
Taro Pharmaceutical Industries Ltd develops, manufactures & markets prescription & over-the-counter (OTC) pharmaceutical products & active pharmaceutical ingredients (APIs) for use in its finished dosage form products.
» More Articles for NYSE:TARO

Headlines

Articles On GuruFocus.com
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
taro pharma could double Aug 26 2012 
What do people think of TARO Aug 26 2012 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 
Sun Pharmaceutical Extends Tender Offer for Taro Dec 19 2008 

More From Other Websites
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014
Large Cap All Time Highs Today... Aug 12 2014
Taro Provides Results for Quarter Ended June 2014 Aug 07 2014
Small-Cap Funds Are In A Lull Aug 07 2014
Taro to Announce Results for Quarter Ended June 30, 2014 Aug 04 2014
TARO PHARMACEUTICAL INDUSTRIES LTD Financials Jul 09 2014
Today Taro Pharmaceutical Industries (TARO) Hits New Lifetime High Jul 09 2014
Taro Annual Report For Fiscal Year Ended March 31, 2014 on Form 20-F Available Jul 08 2014
Taro Pharmaceuticals: Last Week's Move Is Only The Beginning Jul 02 2014
Salix Pharma Hits A New High On Bullish Clinical-Trial Data Jul 01 2014
Novo, Other Medicals Display Healthy Action Jun 26 2014
Taro: The Best Opportunity In Pharma May 29 2014
Can Taro Pharmaceuticals Inject Some Growth Into Your Portfolio? May 28 2014
Taro Provides Results for Year Ended March 31, 2014 May 27 2014
Actavis Builds Base As Annual Earnings Keep Growing May 23 2014
Taro to Announce Results for Quarter and Year Ended March 31, 2014 May 19 2014
Investors bet Sun Pharma can restore Ranbaxy to health Apr 13 2014
Mylan Bid Gets Rejected, But Generic-Drugmaker Rises Apr 04 2014
Taro Announces Results of Its Extraordinary General Meeting of Shareholders Mar 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK